Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
TOKYO, Mar 31, 2021 – (JCN Newswire) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co.,
Read more